Lucid Diagnostics (LUCD) stock
LUCD · Lucid Diagnostics Inc. · NASDAQ
- Market cap
- $77.7M
- Shares out
- 205.0M
- Open
- $0.3842
- Prev close
- $0.3944
- VWAP
- $0.3743
Today $0.3572 - $0.3928
What is the latest news on LUCD stock?
LUCD fell 3.88% to $0.3791 on Nov 20, 2026. No LUCD story in the last two days; the most recent is below.
Lucid Diagnostics' EsoGuard® now fully reimbursed by Medicare nationwideVeris Health achieved implantable physiological monitor design freeze and initiated 90-day GLP animal study ahead of early 2027 FDA submissionPAVmed engaged with FDA on PortIO and OcterisConference call and webcast to be held today, November 13, at 8:30 AM ESTNEW YORK, Nov. 13, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid"), Veris Health Inc. ("Ve
All LUCD newsWhen does Lucid Diagnostics report earnings?
Lucid Diagnostics last reported on Nov 12, 2026, the date it announced on Oct 29, 2026. Before that it reported on Aug 13, 2026 and May 14, 2026. On that schedule the next report would come around mid February 2027, with the date usually announced about 2 weeks ahead.
LUCD earnings historyWho owns the most LUCD stock?
Alyeska Investment Group, L.P. was the largest reported holder of LUCD at the end of Q2 2026, with 8,856,844 shares worth $9.5 million. Next came BlackRock, Inc. ($9.0 million) and Vanguard Capital Management LLC ($7.0 million). In all, 116 institutions reported $65.7 million of LUCD in their 13F filings.
All LUCD fund holdersAre insiders buying or selling LUCD?
No LUCD insider has reported a purchase or sale in the last 90 days. The last trade on file: Dennis Matheis bought $245K, reported on May 21, 2026.
LUCD insider tradesFinancial highlights
Full financials- Revenue, TTM
- $5.44M
- Revenue growth
- +23.6%
- Net income, TTM
- -$48.54M
- Net margin
- -892.8%
- Free cash flow, TTM
- -$51.83M
- Cash
- $17.99M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
Latest news
25 items- PRPAVmed Provides Business Update and Reports Preliminary Third Quarter 2026 Financial ResultsLucid Diagnostics' EsoGuard® now fully reimbursed by Medicare nationwideVeris Health achieved implantable physiological monitor design freeze and initiated 90-day GLP animal study ahead of early 2027 FDA submissionPAVmed engaged with FDA on PortIO and OcterisConference call and webcast to be held today, November 13, at 8:30 AM ESTNEW YORK, Nov. 13, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid"), Veris Health Inc. ("Ve
- SECSEC Form 10-Q filed by Lucid Diagnostics Inc.10-Q - Lucid Diagnostics Inc. (0001799011) (Filer)
- SECLucid Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Lucid Diagnostics Inc. (0001799011) (Filer)
- PRLucid Diagnostics Provides Business Update and Reports Third Quarter 2026 Financial ResultsEsoGuard® now fully reimbursed by Medicare nationwide, launching a new phase of accelerating commercialization with record monthly test volume to start the fourth quarterConference call and webcast to be held today, November 12, at 8:30 AM ESTNEW YORK, Nov. 12, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM) ("PAVmed"), today provided a business update and reported financial results for the third quarter ended September 30, 2026. Conference Call and WebcastThe webcast will take plac
- PRLucid Diagnostics Recognized as a GenomeWeb Best Place to Work for Second Consecutive YearNEW YORK, Nov. 5, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it has been named a GenomeWeb 2026 Best Places to Work honoree, marking its second consecutive year in the annual program recognizing top workplaces across the life sciences research, diagnostics and precision medicine sectors. "Our team's shared passion and relentless dedication to preventing esophageal cancer are the foundation of our success," said Shaun O'Neil, President and Chief Operating O
- PRLucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services ForumNEW YORK, Nov. 4, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, being held November 11, 2026 in New York City. Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will participate in a panel discussion titled "Promising Oncology Diagnostics Navigating the Reimbursement Roadmap" on Wednesday, November 11, 2026 at 3:30 p.m. ET. The panel will not
- PRLucid Diagnostics Announces Publication of Landmark 12,000-Patient Real-World EsoGuard® StudyLargest peer-reviewed study of nonendoscopic esophageal precancer testing to date demonstrates the efficiency and scalability of EsoCheck® cell collection in under two minutes NEW YORK, Nov. 3, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the peer-reviewed publication of findings from the largest real-world clinical experience of nonendoscopic esophageal precancer testing to date, using the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device.
- PRPAVmed to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 13, 2026Conference Call and Webcast at 8:30 AM ETNEW YORK, Oct. 30, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Friday, November 13, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Company's third quarter 2026 financial
- PRLucid Diagnostics to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 12, 2026Conference Call and Webcast at 8:30 AM ETNEW YORK, Oct. 29, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will host a business update conference call and webcast on Thursday, November 12, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's third quarter 2026 financial results.
- PROil Above $100 Puts Penny Stocks in FocusDENVER, Oct. 23, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — With U.S. crude hovering above $100 a barrel, investors are looking beyond the energy trade for smaller companies with potentially transformative technologies and upcoming commercial catalysts. 247 Market News is tracking Kraig Biocraft Laboratories (OTCQB:KBLB), Hyperscale Data (NYSEAMERICAN: GPUS), Lucid Diagnostics (NASDAQ:LUCD), and 22nd Century Group (NASDAQ:XXII). KBLB Moves Spider Silk Toward Commercial Applications Kraig Biocraft Laboratories (OTCQB:KBLB) has taken a notable step toward commercialization, recently shipping its first commercial order of recombinant spider silk yarn to a globally recognized performance
- SECSEC Form 8-K filed by Lucid Diagnostics Inc.8-K - Lucid Diagnostics Inc. (0001799011) (Filer)
- PRLucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million FinancingLucid is now submitting Medicare claims and receiving payments at EsoGuard's established Clinical Laboratory Fee Schedule rateSeries C Preferred Stock private placement with existing long-term shareholders strengthens Lucid's balance sheet, extends its cash runway, and supports near-term commercial accelerationNEW YORK, Oct. 22, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it has begun receiving payments from Medicare for its EsoGuard® Esophageal DNA Test. The Company also closed a $15.0 million private placement on Octob
- SECSEC Form 8-K filed by Lucid Diagnostics Inc.8-K - Lucid Diagnostics Inc. (0001799011) (Filer)
- SECLucid Diagnostics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Lucid Diagnostics Inc. (0001799011) (Filer)
- PRLucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding PathwaysMedicare Advisory Panel recommends maintaining EsoGuard's original gapfill payment basis under the Clinical Laboratory Fee ScheduleAMA CPT Editorial Panel approves a new Category III CPT code for non-endoscopic cell collection procedures performed with EsoCheckProposal for a new ICD-10-CM diagnosis code identifying positive EsoGuard results draws a favorable response from the CDC/NCHS ICD-10 Coordination and Maintenance CommitteeNEW YORK, Sept. 22, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced advances in multiple payment, bill
- PRPAVmed Provides Business Update and Reports Second Quarter 2026 Financial ResultsVeris Health accelerated its commercial engagement with OSU-The JamesVeris Health implantable physiological monitor achieved development milestones towards upcoming FDA submissionLucid Diagnostics secured first laboratory benefit manager coverage policy for EsoGuard ®Conference call and webcast to be held today, August 14, at 8:30 AM EDTNEW YORK, Aug. 14, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid"), Veris Health In
- SECLucid Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Lucid Diagnostics Inc. (0001799011) (Filer)
- PRLucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial ResultsRecognized 2Q26 revenue of $1.5 millionProcessed 2,770 EsoGuard ® testsSecured first laboratory benefit manager (LBM) EsoGuard coverage policyConference call and webcast to be held today, August 13, at 8:30 AM EDTNEW YORK, Aug. 13, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM) ("PAVmed"), today provided a business update for the Company and reported financial results for the second quarter ended June 30, 2026. Conference Call and WebcastThe webcast will take place on Thursday, Aug
- SECSEC Form 10-Q filed by Lucid Diagnostics Inc.10-Q - Lucid Diagnostics Inc. (0001799011) (Filer)
- PRLucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA TestConcert's policy recognizes EsoGuard ® as the only esophageal precancer test meeting its coverage criteriaNEW YORK, Aug. 5, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that Concert, a healthcare technology company recently acquired by Lyric, issued a positive coverage policy effective July 2026 for non-invasive screening of esophageal precancer and cancer. Concert establishes coverage policies that its client health plans can adopt. The policy cites sufficient e
- PRLucid Diagnostics to Participate in Upcoming Investor ConferencesNEW YORK, Aug. 4, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that management will participate in the following upcoming investor conferences: 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference 1x1 Meetings: August 10, 2026Location: VirtualCanaccord Genuity 46th Annual Growth Conference Fireside Chat: August 11, 2026, at 11:30 AM ETLocation: Boston, MAThe live and archived webcast of the Canaccord Genuity fireside chat can be accessed by clicking
- PRPAVmed to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 14, 2026Conference Call and Webcast at 8:30 AM ETNEW YORK, July 31, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Friday, August 14, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Company's second quarter 2026 financial r
- PRLucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026Conference Call and Webcast at 8:30 AM ETNEW YORK, July 30, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will host a business update conference call and webcast on Thursday, August 13, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's second quarter 2026 financial results.
- SECLucid Diagnostics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Lucid Diagnostics Inc. (0001799011) (Filer)
- INSIDERDirector Matheis Dennis bought $245,270 worth of shares (245,000 units at $1.00), increasing direct ownership by 31% to 1,033,443 units (SEC Form 4)4 - Lucid Diagnostics Inc. (0001799011) (Issuer)
- Other5(33%)
- SEC Filings5(33%)
- Earnings4(27%)
- Dividends1(7%)
Lucid Diagnostics Inc. (LUCD) is a Medical/Dental Instruments company listed on NASDAQ. In the last 30 days Quantisnow tracked 10 wire items for LUCD, including 4 press releases and news items, 4 earnings updates and 2 SEC filings. The most recent was published Nov 13, 2026.
LUCD FAQ
10 questionsWhat does Lucid Diagnostics Inc. do?
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company's lead products include EsoGuard, a laboratory developed esophageal DNA test that examines individuals DNA molecules for the presence or absence of cytosine methylation; and EsoCheck, a cell collection device that collects cells of targeted region of...What is LUCD revenue?
Lucid Diagnostics Inc. (LUCD) reported $5.44M of revenue for the twelve months ended Sep 30, 2026. That is up 23.6% from the year before. Revenue for fiscal 2025 was $4.71M.Is LUCD profitable?
No. Lucid Diagnostics Inc. reported a net loss of $48.54M for the twelve months ended Sep 30, 2026.How much cash and debt does LUCD have?
Lucid Diagnostics Inc. reported $17.99M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does LUCD stock trade?
Lucid Diagnostics Inc. (LUCD) is listed on NASDAQ.What sector and industry is LUCD in?
Lucid Diagnostics Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Lucid Diagnostics Inc. go public?
Lucid Diagnostics Inc. (LUCD) completed its IPO in 2021.What are analysts saying about LUCD?
Lucid Diagnostics Inc. has had 6 recent analyst actions on file. The most recent action was from Ascendiant Capital: Buy with a $16.00 price target on 2021-12-27. Recent price targets range from $13.00 to $21.00.What companies are similar to LUCD?
Notable peers in the same industry include BSX (Boston Scientific Corporation), RMD (ResMed Inc.), MDLN (Medline Inc.), DXCM (DexCom Inc.), MMM (3M Company). Compare LUCD side-by-side with any of them on Quantisnow.How can I track LUCD on Quantisnow?
Quantisnow aggregates Lucid Diagnostics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LUCD to receive live email and push alerts on every new disclosure.
Is something on this page wrong, or out of date? Request a change